Envista Holdings Corporation has announced its financial results for Q4 2024, showing steady performance despite a transitional year. CEO Paul Keel emphasized the company’s progress in operational improvements and growth initiatives.
Envista Holdings Corporation
Q4 2024 Highlights:
- Sales reached $653 million, reflecting a 2.0% core sales increase from Q4 2023.
- Adjusted EBITDA margin stood at 13.9%, aligning with expectations.
- Strong performance in dental implants, including Nobel Biocare, Implant Direct, and Alpha-Bio.
- Spark aligners continued to gain market share and improved gross margins.
- Operating cash flow surged 30% to $132 million, while free cash flow increased 24% to $124 million.
Financially, Envista posted a net income of $1 million for the quarter, a significant rebound from a $217 million loss in Q4 2023. Adjusted net income came in at $41 million, with an adjusted diluted EPS of $0.24.
Looking ahead to 2025, Envista projects:
- Core sales growth between 1% and 3%.
- Adjusted EBITDA margins around 14%.
- Adjusted EPS in the range of $0.95 to $1.05.
The company will discuss its results and future outlook in a webcast available on its website.
Envista, a leader in the global dental industry, offers innovative solutions through brands like Nobel Biocare, Ormco, DEXIS, and Kerr. The company remains focused on enhancing patient care with advanced dental technologies and services.
For more details, visit www.envistaco.com.
